Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
3.750
+0.090 (2.46%)
Oct 8, 2025, 2:16 PM EDT - Market open
Nuvation Bio Revenue
Nuvation Bio had revenue of $4.83M in the quarter ending June 30, 2025, with 236.79% growth. This brings the company's revenue in the last twelve months to $14.36M, up 900.35% year-over-year. In the year 2024, Nuvation Bio had annual revenue of $7.87M.
Revenue (ttm)
$14.36M
Revenue Growth
+900.35%
P/S Ratio
82.27
Revenue / Employee
$65,250
Employees
220
Market Cap
1.28B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.87M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NUVB News
- 8 days ago - Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Business Wire
- 9 days ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 19 days ago - Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire
- 23 days ago - Nuvation Bio: A Rare Gem In The Risky Biotech Space - Seeking Alpha
- 4 weeks ago - Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer - Business Wire
- 4 weeks ago - Top 2 Health Care Stocks That May Plunge This Month - Benzinga
- 5 weeks ago - Nuvation Bio: What To Expect From IBTROZI Launch? - Seeking Alpha
- 5 weeks ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire